Thomas Jefferson University

Jefferson Digital Commons
Department of Stem Cell Biology and
Regenerative Medicine Faculty Papers &
Presentations

Department of Stem Cell Biology and
Regenerative Medicine

9-24-2013

Scavenger receptor class B type I regulates cellular cholesterol
metabolism and cell signaling associated with breast cancer
development.
Christiane Danilo
Thomas Jefferson University

Jorge L Gutierrez-Pajares
Thomas Jefferson University

Maria Antonietta Mainieri
Thomas Jefferson University
Follow this and additional works at: https://jdc.jefferson.edu/stem_regenerativefp

Isabelle Mercier

Part of
the Medical
Biochemistry Commons, and the Medical Molecular Biology Commons
Thomas
Jefferson
University

Let
us know how access to this document benefits you
Michael P. Lisanti
Thomas Jefferson University

Recommended Citation
Danilo, Christiane; Gutierrez-Pajares, Jorge L; Mainieri, Maria Antonietta; Mercier, Isabelle;
See next page for additional authors
Lisanti, Michael P.; and Frank, Philippe G., "Scavenger receptor class B type I regulates cellular
cholesterol metabolism and cell signaling associated with breast cancer development." (2013).
Department of Stem Cell Biology and Regenerative Medicine Faculty Papers & Presentations.
Paper 16.
https://jdc.jefferson.edu/stem_regenerativefp/16
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Stem Cell Biology and Regenerative Medicine Faculty Papers &
Presentations by an authorized administrator of the Jefferson Digital Commons. For more information, please
contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Christiane Danilo, Jorge L Gutierrez-Pajares, Maria Antonietta Mainieri, Isabelle Mercier, Michael P. Lisanti,
and Philippe G. Frank

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/stem_regenerativefp/16

Scavenger receptor class B type I regulates cellular
cholesterol metabolism and cell signaling associated
with breast cancer development
Christiane Danilo1
Email: christianed@gmail.com
Jorge L Gutierrez-Pajares1
Email: jlgutierrez2005@gmail.com
Maria Antonietta Mainieri1
Email: ma.mainieri@gmail.com
Isabelle Mercier1
Email: isabelle.mercier@jefferson.edu
Michael P Lisanti2
Email: michaelp.lisanti@gmail.com
Philippe G Frank1,3,*
Email: Philippe.Frank@jefferson.edu
1

Department of Stem Cell Biology and Regenerative Medicine, Kimmel Cancer
Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
2

Manchester Breast Centre & Breakthrough Breast Cancer Research Unit;
Paterson Institute for Cancer Research; Institute of Cancer Sciences; Manchester
Academic Health Science Centre, University of Manchester, Manchester, UK
3

Department of Biochemistry and Molecular Biology, Kimmel Cancer Center,
Thomas Jefferson University, Philadelphia, PA 19107, USA
*

Corresponding author. Department of Biochemistry and Molecular Biology,
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107,
USA

Abstract
Introduction
Previous studies have identified cholesterol as an important regulator of breast cancer
development. High-density lipoprotein (HDL) and its cellular receptor, scavenger receptor
class B type I (SR-BI) have both been implicated in the regulation of cellular cholesterol
homeostasis, but their functions in cancer remain to be established.

Methods
In the present study, we have examined the role of HDL and SR-BI in the regulation of
cellular signaling pathways in breast cancer cell lines and in the development of tumor in a
mouse xenograft model.

Results
Our data show that HDL is capable of stimulating migration and can activate signal
transduction pathways in the two human breast cancer cell lines, MDA-MB-231 and MCF7.
Furthermore, we also show that knockdown of the HDL receptor, SR-BI, attenuates HDLinduced activation of the Phosphatidylinositol 3-kinase (PI3K)/Protein Kinase B (Akt)
pathway in both cell lines. Additional investigations show that inhibition of the PI3K
pathway, but not that of the mitogen-activated protein kinase (MAPK) pathway, could lead to
a reduction in cellular proliferation in the absence of SR-BI. Importantly, while the
knockdown of SR-BI led to decreased proliferation and migration in vitro, it also led to a
significant reduction in tumor growth in vivo. Most importantly, we also show that
pharmacological inhibition of SR-BI can attenuate signaling and lead to decreased cellular
proliferation in vitro. Taken together, our data indicate that both cholesteryl ester entry via
HDL-SR-BI and Akt signaling play an essential role in the regulation of cellular proliferation
and migration, and, eventually, tumor growth.

Conclusions
These results identify SR-BI as a potential target for the treatment of breast cancer.

Introduction
Breast cancer is estimated to have affected over 200,000 women in the United States in 2012
and will be responsible for approximately 40,000 deaths, making it the second leading cause
of cancer deaths [1]. Recently, attention has focused on examining the role of components of
the diet, such as cholesterol, in breast cancer development. Plasma cholesterol levels are often
lower in patients with advanced lung [2] and breast cancers [3-5], a phenomenon known as
the “preclinical effect of cancer” [6]. This effect is believed to be consequential and not
causal [6] but does suggest a role for cholesterol in cancer. Several epidemiologic studies
have shown a positive correlation between elevated high density lipoprotein cholesterol
(HDL-C) levels and breast cancer risk [5,7-9], and recent data have corroborated this claim
[10-16]. In vivo works have suggested that hypercholesterolemia induced by diet and/or
genetic background leads to increased tumor burden and metastasis in murine breast cancer
models [10,12]. In vitro analyses have shown that human breast cancer cell lines exhibit
increased proliferation and migration in the presence of HDL [11,13,15-17]. The effect of
cholesterol on breast cancer may be attributed to several of its properties and functions.
Cholesterol is the precursor of bioactive steroid hormones such as estrogen. It is also
necessary for the formation of plasma membrane microdomains known as lipid rafts [18].
Lipid rafts are believed to organize signaling molecules in the plasma membrane and, as a
result, have been implicated in the development of human cancers [19]. Therefore,
cholesterol may play an essential role in the regulation of tumor growth [20,21].

The HDL lipoprotein is an important carrier of plasma cholesterol and can function as a
signaling molecule by initiating MAPK and AKT signaling pathways and stimulate migration
in endothelial cells [22-24]. The activation of these signaling pathways is dependent on HDL
binding to the HDL receptor, the scavenger receptor class B, type I (SR-BI) and subsequent
lipid transfer to the cell [25-27]. SR-BI functions as the HDL receptor and has been shown to
mediate the selective transfer of cholesteryl ester from HDL molecules to cells in a process
known as the selective HDL-cholesteryl ester uptake [28]. Its role in the development of
atherosclerosis has been well documented [28], but its role in cancer has not been extensively
investigated. Nevertheless, SR-BI has been implicated in prostate [29] and breast cancer
[15,30]. In the case of breast cancer, SR-BI protein levels were found to be increased in
malignant tissue samples compared to the normal surrounding tissue [30].
In the present study, we have examined the role of HDL and SR-BI in the regulation of
cellular signaling pathways in breast cancer cell lines and in the development of tumors in a
mouse xenograft model. Our data show that HDL can stimulate migration and can activate
signal transduction pathways in the two human breast cancer cell lines, MDA-MB-231 and
MCF7. Furthermore, we also show that knockdown of the HDL receptor, SR-BI, attenuates
HDL-induced activation of the MAPK and PI3K/Akt pathways in both cells lines. A more
detailed analysis revealed that SR-BI regulates signaling pathways via Akt activation, and the
regulation of SR-BI expression or activity could limit tumor development in a mouse model.

Methods
Materials
The following antibodies were used: SR-BI was from Novus Biologicals, Inc. (Littleton, CO).
CD31 antibody was from Abcam, Inc. (Cambridge, MA). Phospho-Erk1/2 (T202/Y204),
Erk1/2, Phospho-Akt (S473), and Akt were from Cell Signaling Technology, Inc. (Beverly,
MA). GAPDH was from Fitzgerald Industries International (Acton, MA), and β-Actin was
from Sigma-Aldrich Corp. (St. Louis, MO). Anti-mouse secondary antibody was from
Thermo Fisher Scientific, Inc. (Rockford, IL) and anti-rabbit secondary antibody was from
BD Biosciences (San Jose, CA). The signaling inhibitors U0126 and LY294002 were from
Cell Signaling Technology and Sigma-Aldrich, respectively. BLT-1 was from EMD
Millipore (Billerica, MA).

Cell culture
MCF7 cells were obtained from the American Tissue Culture Collection (ATCC) (Manassas,
VA) and MDA-MB-231 cells were as previously described [31]. MDA-MB-231 and MCF7
cells were grown in Dulbecco’s modified Eagle’s media (DMEM) containing 10% Fetal
Bovine Serum (FBS) in an incubator kept at 37°C with 5% CO2.

Purification of lipoproteins
Human plasma was obtained from adult female volunteers. Approval for the use of human
plasma was obtained from the Office of Human Research at Thomas Jefferson University,
and consent was obtained from the volunteers for the use of their plasma samples.
Lipoproteins [LDL (1.019-1.063 g/mL), HDL2 (1.063-1.125 g/mL), HDL3 (1.125-1.21 g/mL]
were separated by density gradient ultracentrifugation as previously described [32]. HDL3

was dialyzed against PBS, 0.5 mM EDTA, 1% NaN3. In experiments with MCF7 cells,
lipoproteins were stripped of estrogens with activated charcoal to remove endogenous steroid
hormones, as previously described [16].

Migration and invasion assays
Migration was assayed using modified, non-coated Boyden chambers from BD Biosciences
(San Jose, CA). Both MDA-MB-231 and MCF7 cells were cultured in 10-cm dishes in
DMEM containing 10% FBS. Cells were harvested, counted, and washed three times with
PBS. Cells were resuspended in DMEM containing 1% BSA, and 5.0x104 cells were added to
the upper chambers. The bottom chambers contained 1% FBS or 100 µg/mL lipoprotein in
1% BSA. Cells were incubated at 37°C overnight. At the end of the experiment, upper
chambers were swabbed with a cotton swab to remove non-migrating cells, stained with
crystal violet and quantified using phase contrast microscopy. Migration was quantified by
counting the number of cells in 5 separate fields at 10× magnification. Invasion assays were
performed as described above for transwell migration assays but used matrigel-coated
Boyden chambers (BD Biosciences). The upper chambers contained cells in 1% BSA and the
bottom chambers contained 1% FBS or 100 µg/mL lipoprotein in 1% BSA.

Immunoblot analysis
Cells were lysed in radio-immunoprecipitation assay (RIPA) buffer containing protease and
phosphatase inhibitors from Roche Applied Science (Indianapolis, IN) and Sigma-Aldrich
Corp., respectively, prepared and analyzed as previously described [33]. Briefly, proteins
were separated by SDS-PAGE and transferred to a nitrocellulose membrane. Membranes
were blocked in 5% BSA in Tris-buffered saline containing 0.1% Tween-20 (TBS-T).
Primary antibodies were diluted in 5% BSA in TBS-T and incubated for either 1 hour at room
temperature or overnight at 4°C. Membranes were washed three times in TBS-T, and
incubated with horseradish peroxidase-conjugated secondary antibody for 1 hour at room
temperature. Membranes were washed three times in TBS-T, and visualized using Pierce
Chemiluminescent Substrate from Thermo Fisher Scientific, Inc.

Knockdown of SR-BI
MDA-MB-231 and MCF7 stably transfected cell lines were produced by lentiviral
transduction. Lentiviral particles containing a pool of 3 short hairpin RNA (shRNA)
constructs targeted against SR-BI were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Control lentiviral particles containing scrambled shRNA sequences were
also purchased from Santa Cruz. Cells were transduced with the lentiviral particles according
to manufacturer’s protocol. Two days post-transduction, target cells containing either control
shRNA (shCTL) or shRNA against SR-BI (shSRBI) were selected using 2.5 µg/mL
puromycin. Successful knockdown was verified by immunoblot analysis.

Cholesterol content determination
Cells were grown to confluence in 10-cm dishes in the presence of complete media (DMEM,
10% FBS). In half of the plates cholesterol was extracted with isopropanol. The extract was
dried down in glass tubes under nitrogen and re-solubilized in a smaller volume of
isopropanol. Cholesterol content was determined using the Cholesterol E kit from Wako

Chemicals USA, Inc. (Richmond, VA) as per the manufacturer’s instructions. In the other
plates, cells were lysed with 0.5 NaOH, and lysates were collected. Protein concentration was
determined by the bicinchoninic acid assay (BCA) from Thermo Fisher Scientific as per the
manufacturer’s instruction. Total cellular cholesterol levels were calculated by dividing the
total cholesterol by the total protein per dish.
3

H-Thymidine incorporation proliferation assays

Cell proliferation was measured by [3H]-thymidine incorporation to assess DNA synthesis
and proliferation. MDA-MB-231 cells were seeded (5.0x104 cells/well) in 12-well plates in 1
mL of DMEM containing 10% fetal bovine serum (FBS) and grown overnight. The following
day, media was aspirated, cells were washed twice with PBS and were serum-starved with
1% fatty acid free bovine serum albumin (BSA) for 1 hour. Media containing FBS, 1% BSA,
or 1% BSA with lipoproteins (100 µg/mL) and 1 µCi/mL of 3H-thymidine from Perkin Elmer
(Waltham, MA) was added to cells. Cells were incubated for 6 hours at which time media
was removed, cells were washed twice with PBS and incubated in 10% trichloroacetic acid to
precipitate DNA. Cells were solubilized in 0.1 M NaOH and 1% SDS. Radioactivity was
measured by liquid scintillation counting. Protein concentration was determined using the
BCA assay.

Tumor studies
All mice were housed and maintained in a barrier facility at the Kimmel Cancer Center at
Thomas Jefferson University. Mice used in this study were athymic nude mice obtained from
Taconic (Hudson, NY). Animal protocols used for these studies were approved by the
Institutional Animal Care and Use Committee of Thomas Jefferson University. MDA-MB231 (106 ) cells containing either shRNA targeted against SR-BI (shSRBI) or control shRNA
containing scrambled shRNA (shCTL) were subcutaneously injected in the flank of 7–9 week
old nude mice. MCF7 cells (5 × 106) were orthotopically injected into the mammary fat pad
of 9 week-old athymic nude mice implanted with slow release 17β-estradiol pellets
(0.36mg/pellet, 60 days) from Innovative Research of America (Sarasota, FL). Four weeks
post-injection, tumors were excised, weighed, and the volume was determined using the
formula (width2 x length)/2. Half of each tumor was flash frozen and stored at −80°C and
subsequently homogenized and lysed in RIPA buffer for immunoblot analysis as previously
described [33]. The other half was fixed in formalin for 24 hours and then used to prepare
paraffin-embedded sections.

Immunohistochemical analysis
Paraffin-embedded tumor sections were deparaffinized in xylene and rehydrated. Antigen
retrieval was performed in 10 mM citrate buffer pH6 for 10 min using a pressure cooker.
Endogenous peroxidase activity was blocked with 3% H2O2, and sections were blocked in
10% goat serum obtained from Vector Laboratories, Inc. (Servion, Switzerland) and
incubated with primary antibody overnight at 4°C. Sections were washed three times with
PBS, incubated with biotinylated secondary antibody for 30 minutes followed by HRPconjugated streptavidin for 30 minutes using a Streptavidin-HRP kit from Dako North
America, Inc. (Carpinteria, CA). After 3 washes in PBS, the presence of bound antibody was
visualized using 3,3′ diaminobenzidine (DAB). Slides were counterstained with hematoxylin,
dehydrated, and mounted with coverslips.

TUNEL assay
Apoptosis was measured by TUNEL assay using the TUNEL-based ApopTag Peroxidase In
Situ Apoptosis Detection Kit from Millipore (Temecula, CA) as per manufacturer’s
instructions. Briefly, paraffin-embedded tumor sections were de-paraffinized and rehydrated.
Sections were treated with 20 µg/ml proteinase K from Roche Applied Science (Indianapolis,
IN) for 15 min at room temperature and washed, and peroxidase activity was blocked by
incubation in 3% hydrogen peroxide for 5 min. Sections were then incubated with
equilibration buffer, followed by incubation in TdT enzyme for 1 h at 37°C. After washing,
sections were incubated with HRP-conjugated antibody directed again digoxigenin for 30
min at RT, washed, and apoptotic positive cells were visualized using DAB. The percentage
of apoptotic cells was quantified by dividing the number of TUNEL positive cells by the total
number of cells observed in four distinct fields per section.

Statistical analyses
All values are expressed as the mean ± standard deviation (SD). The Prism 4.0 program
(GraphPad Software, Inc., San Diego, CA) was used for statistical analysis. Statistical
significance was examined using the Student’s t test or ANOVA when appropriate.

Results
HDL3 stimulates migration and activates Akt and Erk1/2 in MCF7 and MDAMB-231 cells
Previous studies have shown that HDL can induce migration of endothelial cells [24]. In
cancer, tumor cell migration represents the initial step associated with the development of
metastasis [34]. To examine the effect of HDL on breast cancer cell migration, we studied the
effect of lipoproteins on the migration of two breast cancer cell lines, MCF7 and MDA-MB231. Interestingly, we found that when HDL3 was used as the chemoattractant, it induced
migration of both MCF7 and MDA-MB-231 cells by 3.5 and 61 fold, respectively, compared
to the controls (CTL) as a chemoattractant (Figure 1A and B). Interestingly, LDL had no
effect on the migration of neither MCF7 nor MDA-MB-231 cells (Figure 1A and B). Since
lipoproteins, specifically HDL, can act as signaling molecules in endothelial cells and
prostate cancer cells and activate Akt and MAPK pathways [23,35], we examined their effect
on signaling in MCF7 and MDA-MB-231 cells. However, HDL3 (100µg/mL) stimulated the
activation of Erk1/2 and Akt in both MCF7 and MDA-MB-231 cells (Figure 1C). A modest
increase in the phosphorylation of Erk1/2 was observed in MDA-MB-231 cells after 30
minutes of incubation with HDL3. However, a more robust and quicker response was
observed in MCF7 cells (Figure 1C). Additionally, HDL3 rapidly activated Akt in both cell
lines, an effect that was prolonged in MCF7 cells (Figure 1C). These results indicate that
HDL3 can function as a signaling molecule in these two breast cancer cell lines. LDL had a
modest effect on Akt activation, and no effect on Erk1/2 activation in neither MDA-MB-231
nor MCF-7 cells was observed (Figure 1D).

Figure 1 HDL3 induces migration and acts as a signaling molecule in MDA-MB-231 and
MCF7 cells. A. and B. Migration of MCF7 (A.) and MDA-MB-231 (B.) cells was induced
by HDL3. Migration of MCF7 and MDA-MB-231 cells was increased when HDL3, but not
LDL, was used as a chemoattractant compared to CTL (1% BSA alone) in Boyden Chamber
assays. Stained cells were quantified using phase contrast microscopy. Columns represent the
mean number of migrated cells; bars represent ± standard deviation (SD) (n=3). The results
obtained with CTL and HDL3 groups are significantly different. There was no statistical
difference between CTL and LDL groups. (A. *P< 0.05 Student’s t test, B. **P<0.01, versus
1% BSA by Student’s t test). Results shown are representative of three independent
experiments. C. MDA-MB-231 and MCF7 cells were incubated for the indicated amounts of
time with 100 µg/mL HDL3. Whole cell lysates were analyzed by Western blotting for the
indicated proteins. The arrow indicates the protein corresponding to phospho-Akt. Results are
representative of 3 independent experiments. D. MDA-MB-231 and MCF7 cells were
incubated for the indicated amounts of time with 100 µg/mL LDL. Whole cell lysates were
analyzed by Western blotting for the indicated proteins. The arrow indicates the protein
corresponding to phospho-Akt. Results are representative of 3 independent experiments.

Knockdown of the HDL receptor, SR-BI, attenuates the effects of HDL3 on
signaling in MDA-MB-231 and MCF7 cells
In the following experiments, we examined the effect of downregulating the HDL receptor,
SR-BI, on signaling in MDA-MB-231 and MCF7 cells. As demonstrated in Figure 2, we
were able to successfully downregulate SR-BI in both MDA-MB-231 cells (Figure 2A) and
MCF7 cells (Figure 2B). Knockdown of SR-BI was achieved by stable transduction of a pool
of lentiviral particles containing shRNA sequences specific for SR-BI (shSRBI). shCTL cells
were created by stable transduction of lentiviral particles containing a scrambled version of
the shRNA. Knockdown of SR-BI was assessed by western blot analysis. In MDA-MB-231
cells, SR-BI expression was reduced by 5.3 fold and in MCF7 cells, SR-BI expression was
reduced by 4.0 fold (Figure 2A). To determine the role of SR-BI on the regulation of
signaling pathways, both shCTL and shSRBI MDA-MB-231 and MCF7 cells were serum
starved overnight and then incubated in media containing 10% FBS for 30 minutes or 100
µg/mL of HDL3 for 0, 5, 15 and 30 minutes, as indicated. We found that the activation of Akt
was greatly reduced in the shSRBI cells compared to the shRNA control cells. Similar results
were obtained with both MDA-MB-231 and MCF7 cell lines in the presence of FBS (lanes 1
and 6 in both Figures 2A and 2B). Consistent with the results presented in Figure 1C, HDL3
was able to stimulate the activation of Akt in both cell lines in a time-dependent manner.
However, activation of Akt in shSRBI MDA-MB-231 cells was greatly reduced when
stimulated by HDL3 for 15 and 30 minutes (Figure 2A, lanes 9 and 10), compared to the Akt
activation observed in shCTL MDA-MB-231 cells when stimulated by HDL3 for the same
periods of time (Figure 2A, lanes 4 and 5). Similar results were obtained in MCF7 cells. In
that case, Akt activation was reduced in the shSRBI MCF7 cells when stimulated by HDL3
for 15 and 30 minutes (Figure 2B, lanes 9 and 10), compared to shCTL MCF7 cells
stimulated by HDL3 for the same periods of time (Figure 2B, lanes 4 and 5). Finally, Erk1/2
appeared to be constitutively active in MDA-MB-231 cells (Figure 2A, lanes 1–10).
However, almost no change in Erk1/2 activation was detected in shSRBI MDA-MB-231 cells
treated with HDL3 for 30 minutes (Figure 2A, lane 10) compared to shCTL MDA-MB-231
treated with HDL3 for 30 minutes (Figure 2A, lane 5). This effect was in contrast with
observations made with MCF7 cells (Figure 2B). In shCTL MCF7 cells, HDL3 rapidly
stimulated Erk1/2 activation, reaching a peak at 5 minutes (Figure 2B, lane 3) but
maintaining a sustained effect at 30 minutes (Figure 2B, lanes 4 and 5). Activation of Erk1/2

in shSRBI MCF7 cells followed a similar pattern, but the intensity of activation was greatly
reduced (Figure 2B, lanes 7–10). These results suggest that downregulation of SR-BI in
MDA-MB-231 and MCF7 cells attenuates signaling via the AKT and MAPK pathways.
Additionally, our results also show that the interaction between HDL and SR-BI regulates
activation of these signaling pathways. Finally, the effect of LDL was also tested in these
cells lines. Results presented in Figure 2C and D demonstrate that the downregulation of SRBI in MDA-MB231 and MCF7 cells had no effect on the regulation of Akt and Erk1/2
activation by LDL.
Figure 2 Knockdown of SR-BI attenuates HDL3-induced signal transduction in MDAMB-231 and MCF7 cells. A, B. MDA-MB-231 and MCF7 cells were stably transduced by
lentiviruses carrying either shRNA against SR-BI (shSRBI) or control shRNA (shCTL). Cells
were incubated with either 10% FBS for 30 minutes or with 100 µg/mL HDL3 for the
indicated times. Whole cell lysates were analyzed by Western blot for the indicated proteins.
The arrow indicates the protein corresponding to phospho-Akt. GAPDH was used as loading
control. C, D. MDA-MB-231 and MCF7 cells were stably transduced by lentiviruses carrying
either shRNA against SR-BI (shSRBI) or control shRNA (shCTL). Cells were incubated with
either 10% FBS for 30 minutes or with 100 µg/mL LDL for the indicated times. Whole cell
lysates were analyzed by Western blot for the indicated proteins. The arrow indicates the
protein corresponding to phospho-Akt. GAPDH was used as loading control. Note that, in
panel C, image was spliced (between line 5 and 6) to eliminate an irrelevant line.

Knockdown of the HDL receptor, SR-BI, inhibits proliferation and migration
of MDA-MB-231 cells
We observed decreased signaling in shSRBI MDA-MB-231 cells compared to shCTL MDAMB-231 cells in the presence of FBS. Therefore, we used media containing 10% FBS for the
remainder of the experiments described below. FBS contains large amounts of lipoproteins
and provides suitable ligands for SR-BI. Previous studies have shown that expression of SRBI in COS-7 cells significantly increased cholesterol mass in these cells compared to control
vector-transfected cells [36]. To determine if cellular cholesterol homeostasis was affected by
the downregulation of SR-BI, we quantified the cholesterol content of shCTL and shSRBI
MDA-MB-231 cells. Under basal conditions, shCTL MDA-MB-231 cells contained a
significantly greater (1.3-fold increase) (P<0.01) total cholesterol content compared to
shSRBI MDA-MB-231 cells (Figure 3A).

Figure 3 Knockdown of the HDL receptor, SR-BI, inhibits proliferation, migration, and
invasion of MDA-MB-231 cells. A. Cholesterol content of shCTL and shSRBI MDA-MB231 cells. Cholesterol was extracted from cells with isopropanol, and total cholesterol was
measured enzymatically using a colorimetric assay. Protein concentration was also
determined, and total cellular cholesterol content was expressed as the amount of cholesterol
per milligram of protein. Columns represent the mean cholesterol content and bars represent
± SD. shCTL MDA-MB-231 cells displays significantly more cholesterol than shSRBI
MDA-MB-231 cells (**P<0.01 by student’s t test). B. Knockdown of SR-BI inhibits
proliferation of MDA-MB-231 cells. MDA-MB-231 cells containing control shRNA (shCTL)
or shSRBI were incubated in the presence of 3H-thymidine for 6 hours in DMEM containing
10% FBS. Proliferation was measured by 3H-thymidine incorporation. Columns represent the
mean 3H-Thymidine incorporation (cpm/µg protein); bars represent ± (SD). The results
obtained for shCTL and shSRBI cells are significantly different (*P<0.01 by student’s t test).
Results are representative of three independent experiments. C. Knockdown of SR-BI
reduces cellular migration. Cellular migration of shCTL and shSRBI MDA-MB-231 cells
was assessed for 24h in a Boyden Chamber using 1% FBS as a chemoattractant. Columns
represent the mean number of migrated cells from three independent experiments, bars
represent ± standard deviation (SD), (n=12). The results obtained from the shCTL and
shSRBI groups are significantly different (*P<0.05 versus shCTL, as determined by
student’s t test). D. Knockdown of SR-BI leads to a marginally significant reduction in
cellular invasion. Invasion of shCTL and shSRBI MDA-MB-231 cells was assessed by
matrigel-coated Boyden Chamber Assays using 1% FBS as a chemoattractant. Columns
represent the mean number of invaded cells from three separate experiments (n=12); bars
represent ± SD (P=0.0517, Student’s t test).
Previous studies have shown that a mutant of SR-BI inhibits proliferation of the luminal B
subtype of human breast cancer cells, MCF7, in the presence of HDL [30]. To further
investigate the role of SR-BI in a triple negative (lacking the estrogen receptor (ER),
progesterone receptor (PR), and Her2) basal B subtype breast cancer cell line, we determined
the effect of knocking down SR-BI on the proliferation of MDA-MB-231 cells. The
proliferation of shSRBI MDA-MB-231 cell was reduced by 2.0 fold compared to the
proliferation observed with shCTL MDA-MB-231 cells (P<0.01) (Figure 3B). Knockdown of
SR-BI also significantly reduced cellular migration (P<0.05) by 1.65 fold (Figure 3C).
Finally, a reduction of SR-BI protein levels was associated with a marginally significant
reduction of the ability of MDA-MB-231 cells to invade (Figure 3D) (P=0.0517).

Pharmacological inhibition of SR-BI reduces proliferation and signal
transduction in MDA-MB-231 cells
To further elucidate the inhibitory effect of SR-BI ablation on proliferation and signal
transduction obtained by molecular biological means, we treated cells with the
pharmacological inhibitor of SR-BI, BLT-1 [37]. Previous work has identified BLT-1 as a
specific inhibitor of SR-BI function. BLT-1 has been shown to act by blocking the transfer of
lipids from HDL particles to cells [37]. The IC50 for this compound was determined to be 50
nM [37]. The ability of BLT-1 to regulate proliferation was evaluated in the presence of
varying concentrations of this inhibitor. Accordingly, BLT-1 could inhibit growth of shCTL
MDA-MB-231 cells in a dose-dependent manner (Figure 4A). At doses over 50 nM, BLT-1
treatment could significantly decrease proliferation of shCTL MDA-MB-231 cells compared
to the control untreated cells (P<0.001 for concentrations of 50 nM, 75 nM, and 100 nM
compared to shCTL MDA-MB-231 incubated with 0 nM BLT-1). Importantly, there was no

significant effect of BLT-1 treatment on the proliferation of shSRBI MDA-MB-231 cells:
Proliferation of shSRBI cells treated with concentrations of BLT-1 between 0.1nM and
100nM were not statistically different from that of vehicle-treated shSRBI cells. Interestingly,
there was also no significant difference between shCTL MDA-MB-231 cells treated with
BLT-1 at doses above 20nM and vehicle-treated (0nM) shSRBI MDA-MB-231 cells. Taken
together, these results suggest that down regulation or pharmacological inhibition of SR-BI
have similar effect on MDA-MB-231 proliferation.
Figure 4 Inhibition of SR-BI by the small molecule BLT-1 inhibits proliferation of
MDA-MB-231 cells. A. Pharmacological inhibition of SR-BI in MDA-MB-231 cells inhibits
cellular proliferation. MDA-MB-231 shCTL cells were incubated in the presence of the
indicated doses of BLT-1 and 3H-thymidine added to the culture media for six hours. At this
time, the assay was stopped, and lysates were collected. Columns represent the mean 3Hthymidine incorporation (cpm/µg protein); bars represent ±SD. Results obtained with shSRBI
MDA-MB-231 CTL (0 nM BLT-1) are significantly different from those obtained with
shCTL 0 nM BLT-1 (CTL) (a, P<0.001), shCTL 0.1 nM BLT-1 (b, P<0.001), and shCTL
1.0 nM (c, P<0.05). Results obtained with shCTL MDA-MB-231 CTL (0nM BLT-1) were
significantly different from those obtained with shCTL 50 nM BLT-1 (d, P<0.001), shCTL
75 nM BLT-1 (e, P<0.001), and shCTL 100 nM (f, P<0.001). Significance was determined
by one-way ANOVA with Tukey’s post-test analysis. B. Pharmacological inhibition of SRBI attenuates signaling in MDA-MB-231 cells. Western blot analysis was performed with
extracts obtained from shSRBI MDA-MB-231 cells treated with vehicle, shCTL MDA-MB231 cells treated with vehicle, and shCTL MDA-MB-231 cells treated with BLT-1 (50 nM).
Cells were serum starved overnight, incubated with vehicle alone or BLT-1 for 3 hours, and
then treated with 10% FBS for 30 minutes.
We also examined the effect of BLT-1 on signal transduction in these cells. In agreement
with the finding described in Figure 2A, Akt activation in shSRBI MDA-MB-231 cells
treated with FBS for 30 minutes was reduced compared to shCTL MDA-MB-231 cells
(Figure 4B). Similar results were obtained with shCTL MDA-MB-231 cells with treated
BLT-1. Akt activation was reduced in the treated shCTL MDA-MB-231 cells compared to
untreated control cells. Finally, SR-BI knockdown or pharmacological inhibition had no
effect on Erk1/2 activation (Figure 4B) compared to the control cells. A statistical difference
between untreated shSRBI MDA-MB-231 cells and shSRBI MDA-MB-231 cells treated with
100 nM BLT-1 was also detected. This observation may be due to the presence of some
residual SR-BI protein. Collectively, these data suggest that Akt activation may be mediated,
in part, by SR-BI, and the downregulation of SR-BI is responsible for the observed reduction
in the cellular proliferation.

Inhibition of PI3K, not MEK1/2, inhibits growth of shCTL MDA-MB-231
cells
In order to elucidate the mechanism by which SR-BI knockdown inhibits proliferation, we
used pharmacological agents to inhibit PI3K and MAPK signaling pathways. We show that
the PI3K inhibitor, LY294002, abolished FBS-induced activation of Akt (Figure 5A) in
shCTL and shSRBI MDA-MB-231 cells. Importantly, PI3K inhibition significantly reduced
proliferation of shCTL MDA-MB-231 cells to levels similar to those observed with untreated
shSRBI MDA-MB-231 cells (Figure 5B). In addition, PI3K inhibition had no effect on the
proliferation of shSRBI MDA-MB-231 cells suggesting that downregulation of SR-BI in
these cells was sufficient to inhibit proliferation. Conversely, U0126-induced inhibition of

MEK1/2, which activates Erk1/2, did not affect proliferation of shCTL MDA-MB-231 or
shSRBI MDA-MB-231 cells (Figure 5B). Erk1/2 activation, however, was significantly
reduced by inhibition of MEK1/2 in both cell types (Figure 5A). These results suggest that
the MAPK pathway does not play a significant role in SR-BI-mediated signaling and
proliferation unlike the PI3K pathway.
Figure 5 Inhibition of PI3K, not MEK1/2, prevents proliferation of MDA-MB-231 cells.
A. LY294002 and U0126 effectively inhibit Akt and Erk1/2 activation in MDA-MB-231
cells. Serum-starved shCTL and shSRBI MDA-MB-231 cells were incubated with or without
the inhibitors LY294002 (15 µM) or U0126 (10 µM) for 2 hours. Medium containing 10%
FBS was added for 30 minutes, cells were lysed, and whole cell lysates were analyzed by
Western blot for the indicated proteins. GAPDH was used as a loading control. B. PI3K
inhibition reduces cellular proliferation of shCTL MDA-MB-231 cells. shCTL and shSRBI
MDA-MB-231 cells were incubated with culture media containing either LY294002 (15µM)
or U0126 (10 µM) and 3H-thymidine for 6 hours, at which time the assay was stopped, and
lysates were collected. Columns represent the mean 3H-thymidine incorporation (cpm/µg
protein); bars represent ± SD. Results obtained from vehicle-treated (CTL) shCTL MDAMB-231 cells are significantly different from those obtained with shSRBI MDA-MB-231
cells (**P<0.001, one-way ANOVA with Tukey’s post-test analysis). Results obtained from
vehicle-treated shCTL MDA-MB-231 cells (CTL) are significantly different from those
obtained with shCTL MDA-MB-231 cells treated with LY294002. Note that proliferation of
shCTL MDA-MB-231 cells treated with U0126 was not significantly different from that
observed with vehicle-treated shCTL MDA-MB-231 cells. Proliferation of shSRBI MDAMB-231 cells treated with LY294002 or U0126 was also not significantly different from that
observed with vehicle-treated shCTL MDA-MB-231 cells. Results are representative of three
independent experiments.

Knockdown of SR-BI results in decreases in in vivo tumor growth of MDAMB-231 and MCF7 cells
To assess the effect of SR-BI knockdown in vivo, we subcutaneously injected shSRBI and
shCTL MDA-MB-231 cells in the flanks of nude mice. Four weeks after injection, tumors
were excised from sacrificed mice, and mass and volume were measured. Tumors obtained
with shCTL MDA-MB-231 were significantly larger than those obtained from shSRBI
MDA-MB-231: tumor volume and mass were increased by 3.8 fold and 3.7 fold, respectively
(Figure 6A). To determine the role of SR-BI in tumor growth in MCF7 cells, shCTL and
shSRBI MCF7 cells (5 × 106) were orthotopically injected into the mammary fat pad of
athymic nude mice after implantation with slow release 17β-estradiol pellets. Four weeks
post-injection, mice were sacrificed, tumors were excised, and mass and volume of tumors
were determined (Figure 6B). Tumors obtained with shCTL MCF7 were 1.5-fold larger than
those obtained with shSRBI MCF7 (P<0.05), and 1.3-fold larger by mass (marginally
significant).

Figure 6 Knockdown of SR-BI inhibits xenograft tumor growth in vivo. A. Knockdown
of SR-BI in MDA-MB-231 cells decreases tumor growth in vivo. Athymic nude mice were
injected with 106 MDA-MB-231 cells carrying control shRNA (shCTL) or shSRBI. Four
weeks post-injection, mice were sacrificed, and tumors were excised. Tumors were weighed
and volume determined using the formula (length x width2)/2. Columns represent the mean
volume and mass respectively, bars represent ± SD. Tumors obtained with shCTL cells were
significantly larger by weight and volume than the tumors obtained with shSRBI. (*P<0.05,
n=14 shCTL, n=13 shSRBI) B. Knockdown of SR-BI in MCF7 cells decreases tumor growth
in vivo. MCF7 cells (5×106) were orthotopically injected into the mammary fat pad of 9
week-old athymic nude mice implanted with slow release 17β-estradiol pellets
(0.36mg/pellet, 60 days). Four weeks post injection, mice were sacrificed, and the tumors
were excised. Tumors were weighed and volume determined using the formula (length x
width2)/2. Columns represent the mean volume and mass respectively; bars represent ± SD.
The shCTL tumors were significantly larger by volume than the shSRBI tumors (*P<0.05,
n=8 shCTL, n=7 shSRBI). C. shCTL tumors display increased expression of proliferative
markers compared to shSRBI tumors. Immunohistochemistry was performed to determine
expression patterns of SR-BI and pErk1/2 in MDA-MB231 tumors. D. shCTL tumors display
increased expression of proliferative markers compared to shSRBI tumors. Three tumors per
cell type were analyzed by western blot analysis for the indicated proteins. GAPDH was used
as a loading control.
To elucidate the mechanism by which SR-BI regulates tumor formation, tissue
immunohistochemical analyses (Figure 6C) and immunoblot analyses of homogenized
tumors (Figure 6D) were performed. Immunohistochemistry analyses demonstrated the
reduction in SR-BI protein expression in shSRBI MDA-MB-231-derived tumors compared to
shCTL MDA-MB231. Results also revealed that levels of the proliferative marker, pErk1/2,
were decreased in shSRBI MDA-MB-231 tumors, compared to those observed in control
tumors. Consistent with in vitro findings, pAkt levels were decreased in shSRBI MDA-MB231 tumors compared to those observed in control tumors.
Since cholesterol has been shown to play a role in the regulation of angiogenesis [38],
microvessel density in the tumors was assessed by staining tumor sections for CD31, a
specific marker of endothelial cells (Figure 7A). A significant increase in microvessel density
was observed with tumors obtained from shCTL MDA-MB-231 cells compared to those
obtained from shSRBI MDA-MB-231 cells. These data suggest that SR-BI can regulate
angiogenesis in these tumors. Finally, SR-BI has been shown to activate Akt [23], which may
inhibit apoptosis thereby promoting cell survival [39]. Therefore, we assessed apoptosis by
TUNEL staining in tissue sections obtained from shCTL and shSRBI MDA-MB-231
xenograft tumors (Figure 7B). As anticipated, we observed a significant increase in apoptosis
in shSRBI MDA-MB-231 tumors compared to shCTL MDA-MB-231 tumors.

Figure 7 Knockdown of SR-BI inhibits xenograft tumor growth in vivo. A. Knockdown
of SR-BI results in decreased angiogenesis in MDA-MB-231 xenograft tumors.
Immunohistochemistry was performed to determine expression of CD31. CD31 staining was
quantified by averaging the number of vessels per field in 5 separate fields per sample.
Columns represent the mean microvessel density; bars represent ± SD. Microvessel density
was statistically greater in shCTL MDA-MB-231 tumors compared to shSRBI MDA-MB231 cells (*P<0.05 student’s t test, n=4 per group). B. Knockdown of SR-BI results in
increased apoptosis in MDA-MB-231 xenograft tumors. Images shown are representative of
TUNEL assay staining. Percentage of TUNEL positive cells was calculated by dividing the
number of TUNEL-positive cells by the total number of cells in 4 separate fields. Columns
represent the percent of TUNEL-positive cells; bars represent ± SD. TUNEL staining is
statistically increased in shSRBI MDA-MB-231 tumors compared to shCTL MDA-MB-231
tumors (***P<0.001, student’s t test, shCTL n=3 and shSRBI n=4).

Discussion
In the present study, we have examined the role of HDL and its receptor, SR-BI, in breast
cancer development and progression. We found that HDL3 stimulates migration and activates
signaling pathways such as MAPK and PI3K in two breast cancer cell lines. Inhibiting
selective HDL-cholesteryl ester uptake by knocking down or pharmacologically inhibiting
SR-BI resulted in an attenuation of cell signaling events induced by HDL. Additionally, loss
of SR-BI resulted in decreased proliferation, migration, and tumor growth of MDA-MB-231
cells. These findings suggest that regulating cholesterol metabolism and cellular signaling
pathways via SR-BI may be linked and may additionally identify new targets associated with
tumor progression.

HDL, signal transduction and cellular migration
HDL has a well-established role in the etiology of atherosclerosis, particularly in reverse
cholesterol transport whereby HDL removes excess cholesterol molecules from peripheral
tissues and returns them to the liver for excretion or recycling [40]. In addition, HDL
functions in a number of other cellular processes including inhibition of apoptosis in
macrophages [41], induction of migration in endothelial cells [24], and the initiation of cell
signaling events in multiple cells types [22,23,42]. Although clinical studies have suggested
that plasma HDL levels may be correlated with increased breast cancer [5,7-9,12], the
mechanisms by which HDL exerts its effect have yet to be elucidated. HDL has been shown
to activate Erk1/2 in fibroblasts [23,42], Chinese hamster ovary cells [22], endothelial cells
[23], and prostate cancer cells [35,43]. Studies have also shown that it can activate Akt in
endothelial [23] and prostate cancer cells [35,43]. Interestingly, the activation of Erk1/2 [44]
and Akt [39,45] has been implicated in several human cancers, including breast cancer. In the
present study, we have established a role for HDL as a mediator of signal transduction in two
breast cancer cell lines. Consistent with the results obtained in other cell types, we found that,
in both MCF7 and MDA-MB-231 cells, incubation with HDL3 induces a rapid activation of
both Erk1/2 and Akt signaling pathways. These novel findings in breast cancer suggest that
HDL may regulate various signaling pathways and may therefore alter tumor progression.
In the present study, we found that HDL can induce migration of two breast cancer cell lines,
MCF7 and MDA-MB-231, suggesting that HDL may play a role in the early stages of
metastasis. This finding is consistent with previous studies showing that HDL can stimulate

migration of endothelial cells [24,46]. Interestingly, the observed migration was shown to be
mediated by SR-BI [24]. By contrast, a recent study reported that HDL inhibits migration of
MDA-MB-231 in Boyden chamber assays [14]. However, in this study, the investigators used
serum as the chemoattractant, and HDL was added to the upper chamber, thereby measuring
the ability of HDL to prevent cellular migration induced by serum. By contrast, our method
allows the analysis of the role of HDL in the regulation of cellular migration and therefore
allows a direct measurement of the capability of HDL to induce migration of MDA-MB-231
cells. As a result, our results indicate that HDL may play a role in the pathogenesis of breast
cancer, especially in the later stages.

SR-BI, signal transduction regulation, and tumor formation
SR-BI has been implicated as a mediator of several cell signaling events in the context of
atherosclerosis [22,23,25-27]. Previous studies have shown that HDL binding to SR-BI and
subsequent lipid transfer are sufficient to activate Src, which subsequently activates the
PI3K/Akt and MAPK pathways [25,27]. In endothelial cells, one of the downstream effectors
of Akt is eNOS, which catalyzes the production of NO. The results obtained in the present
study are consistent with the hypothesis that SR-BI may also play a role in signal
transduction in the context of cancer. In agreement with this hypothesis, upon knockdown or
pharmacological inhibition of SR-BI in MDA-MB-231 cells, Akt activation was significantly
reduced, suggesting that SR-BI may be mediating this response. In addition, down-regulation
of SR-BI was accompanied by a reduction of total cholesterol levels in MDA-MB-231 cells.
These results are consistent with reports that indicate that the cholesterol flux mediated by
SR-BI plays a role in the regulation of signal transduction initiation [26]. In our model,
decreased total cholesterol levels may represent a reduction in SR-BI-mediated cholesterol
flux and therefore significantly reduce signal transduction activation. SR-BI also binds LDL,
which can, like HDL, promote the cellular entry of cholesteryl ester. While LDL may
promote the entry of cholesteryl ester via SR-BI, it is not sufficient to induce migration of
breast cancer cells, and it does not appear to alter Akt activation (Figure 2C and D). Taken
together, our data suggest that both cholesteryl ester entry via HDL-SR-BI and Akt activation
are required for cellular proliferation and migration, and, eventually, tumor growth.
Activation of the PI3K/Akt pathway promotes growth, survival, and proliferation [45] and
has been implicated in a variety of human cancers [39]. Importantly, Akt is aberrantly hyperactivated in approximately 40% of breast cancers [39]. Interestingly, we observed a reduction
in proliferation and migration in the SR-BI-knockdown cells compared to control cells in
association with reduced Akt activation. These results suggest that SR-BI may mediate the
activation of Akt and its downstream effects in the presence of HDL. Mechanistically, we
showed that the inhibition of the PI3K/Akt pathway results in significantly reduced
proliferation of shCTL MDA-MB-231 cells similar to the reduction in proliferation observed
in shSRBI MDA-MB-231 cells. Importantly, no further reduction in proliferation of shSRBI
MDA-MB-231 cells was detected upon inhibition of the PI3K/Akt pathway. Taken together,
these data suggest that reduced Akt activation observed in the shSRBI MDA-MB-231 cells
may be responsible for reduced proliferation of these cells compared to shCTL MDA-MB231 cells.
Previous studies have suggested a role for SR-BI in the etiology of breast cancer. Cao et al.
[30] have shown that expression of SR-BI is increased in human breast tumors compared to
the normal surrounding tissue. They also demonstrated that recombinant expression of a
mutant form of SR-BI, which lacked the carboxyl-terminal tail of the protein, could inhibit

proliferation of breast cancer cells. Their study further suggested that this effect was possibly
due to reduced Akt activation. Our study is the first to demonstrate directly that Akt
activation is reduced when SR-BI is knocked down or pharmacologically inhibited.
Furthermore, in agreement with the previously mentioned study [30], we showed that
proliferation of MDA-MB-231 cells was significantly inhibited by downregulation of SR-BI
protein levels and by pharmacological inhibition of SR-BI. In addition, we observed that SRBI knockdown inhibits migration. This finding may suggest a role for SR-BI in the initiation
of metastasis. Finally, we demonstrated that knockdown of SR-BI in MDA-MB-231 cells can
lead to reduced tumor growth in vivo accompanied by increased activation of Erk1/2 and Akt,
and an increase in cellular apoptosis. In MCF7 cells, knockdown of SR-BI also led to reduced
xenograft tumor growth.
Previous studies have shown that Akt can inhibit apoptosis through a variety of mechanisms
including the phosphorylation of BAD, thus preventing cytochrome c release from
mitochondria and the direct inhibition of the caspase activation cascade [39]. Increased
cellular cholesterol levels have been shown to increase Akt activation and decrease apoptosis
in prostate cancer cells [47]. Consistent with these observations, a recent study has shown
that inhibition of xenograft tumor growth could be achieved with colon cancer cells that reexpress the ATP-binding cassette transporter A1 (ABCA1) [48]. ABCA1 is a lipid transporter
that mediates the efflux of cellular cholesterol to lipid free apolipoprotein A-I [49].
Furthermore, in this study, re-expression of ABCA1 resulted in decreased mitochondrial
cholesterol content and increased release of cytochrome c, which ultimately led to increased
apoptosis. Our work also indicated that SR-BI knockdown can significantly reduce apoptosis
in xenograft tumors as shown by TUNEL staining. Consequently, a reduction in the levels of
cellular cholesterol content may be responsible, at least in part, for the decreased apoptosis
observed in our model. Taken together, these data also suggest an important role for
cholesterol in the regulation of cellular signaling pathways and tumor formation. Importantly,
excess cellular cholesterol accumulates in the form of esterified cholesterol. Previous works
and ours suggest that the accumulation of esterified cholesterol may lead to a modification of
signaling pathways associated with proliferation and migration in tumors. Consistent with
this hypothesis, increasing cellular esterified cholesterol levels have been shown to induce
cellular proliferation and enhance invasiveness of tumor cell lines [50]. Conversely, the
inhibition of cholesterol esterification has been shown to have the reverse effect [51,52].

Conclusions
In summary, our results suggest that HDL and SR-BI have pro-oncogenic activity and can
induce migration and activate signal transduction pathways responsible for cellular
proliferation and tumor formation in two breast cancer cell lines. Additionally, knockdown or
pharmacological inhibition of SR-BI could attenuate signaling mediated by HDL and inhibit
proliferation, migration, and tumor growth. Taken together, these findings identify SR-BI and
HDL as potential therapeutic targets for the treatment of breast cancer.
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